{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,23]],"date-time":"2026-04-23T14:30:02Z","timestamp":1776954602046,"version":"3.51.4"},"reference-count":20,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2024,10,21]],"date-time":"2024-10-21T00:00:00Z","timestamp":1729468800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Cardiovasc. Med."],"abstract":"<jats:sec><jats:title>Introduction<\/jats:title><jats:p>There is no consensus on the optimal concentration of lipoprotein(a) (Lp(a)) for the risk of atherosclerotic cardiovascular diseases (ASCVD) and aortic valve stenosis. In various clinical guidelines and agreed documents, the threshold level of Lp (a) is 30\u2009mg\/dl or 50\u2009mg\/dl. We estimated the cut-off value of Lp (a) associated with the risk of developing various localizations of atherosclerosis for the Central Asia, including Kazakhstani population.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>This study was conducted at National Research Cardiac Surgery Center, Kazakhstan. 487 patients were included, of which 61.3% were men. The mean age of all participants was 57.3\u2009\u00b1\u200912.6 years. Bivariate and multivariable logistic regression analysis was used to study the relationship between risk factors and plasma lipoprotein (a) levels. The threshold value of lipoprotein (a) was predicted using the Youden index.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>For Kazakhstani population the lipoprotein (a) cut offs for the risk of developing atherosclerotic CVD and aortic valve calcification was 21.1\u2009mg\/dl (<jats:italic>p<\/jats:italic>\u2009&amp;lt;\u20090.05). There was no relationship with the level of lipoprotein (a) and low-density lipoprotein cholesterol (LDL-C), which suggests that lipoprotein (a) is an independent risk factor for the development of ASCVD.<\/jats:p><\/jats:sec><jats:sec><jats:title>Discussion<\/jats:title><jats:p>This study offers new insights into the threshold value of lipoprotein (a) in Kazakhstan, highlighting its role as a risk factor for atherosclerotic cardiovascular diseases and aortic valve calcification. The findings suggest that the internationally recommended Lp(a) cutoffs may not be suitable for Central Asian populations, as the threshold in our study is significantly lower at 21.2\u2009mg\/dL. These results emphasize the need for further research with larger sample sizes to establish more region-specific cutoffs.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fcvm.2024.1468566","type":"journal-article","created":{"date-parts":[[2024,10,21]],"date-time":"2024-10-21T04:40:26Z","timestamp":1729485626000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":4,"title":["Proposing new lipoprotein (a) cut off value for Kazakhstan: pilot study"],"prefix":"10.3389","volume":"11","author":[{"given":"Makhabbat","family":"Bekbossynova","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marat","family":"Aripov","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tatyana","family":"Ivanova-Razumova","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aknur","family":"Kali","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dana","family":"Tleubayeva","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gulnur","family":"Daniyarova","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alexey","family":"Goncharov","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2024,10,21]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1093\/eurheartj\/ehz455","article-title":"2019 ESC\/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk: the task force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and European atherosclerosis society (EAS)","volume":"41","author":"Mach","year":"2020","journal-title":"Eur Heart J"},{"key":"B2","doi-asserted-by":"publisher","first-page":"e1082","DOI":"10.1161\/CIR.0000000000000625","article-title":"2018 AHA\/ACC\/AACVPR\/AAPA\/ABC\/ACPM\/ADA\/AGS\/APhA\/ASPC\/NLA\/PCNA guideline on the management of blood cholesterol: executive summary: a report of the American College of Cardiology\/American Heart Association task force on clinical practice guidelines","volume":"139","author":"Grundy","year":"2019","journal-title":"Circulation"},{"key":"B3","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1016\/j.atherosclerosis.2022.04.005","article-title":"Lipoprotein (a) and ethnicities","volume":"349","author":"Mehta","year":"2022","journal-title":"Atherosclerosis"},{"key":"B4","doi-asserted-by":"publisher","first-page":"1082","DOI":"10.1161\/01.CIR.102.10.1082","article-title":"Lipoprotein(a) and coronary heart disease: meta-analysis of prospective studies","volume":"102","author":"Danesh","year":"2000","journal-title":"Circulation"},{"key":"B5","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1093\/eurjpc\/zwac300","article-title":"Elevated lipoprotein (a) levels in east Asia: bridging the ethnicity data gap","volume":"30","author":"Fang","year":"2023","journal-title":"Eur J Prev Cardiol"},{"key":"B6","doi-asserted-by":"publisher","first-page":"1003","DOI":"10.1161\/ATVBAHA.115.306683","article-title":"Lipoprotein(a) levels are associated with subclinical calcific aortic valve disease in white and black individuals: the multi-ethnic study of atherosclerosis","volume":"36","author":"Cao","year":"2016","journal-title":"Arterioscler, Thromb, Vasc Biol"},{"key":"B7","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1097\/MOL.0000000000000753","article-title":"The impact of race and ethnicity on lipoprotein (a) levels and cardiovascular risk","volume":"32","author":"Reyes-Soffer","year":"2021","journal-title":"Curr Opin Lipidol"},{"key":"B8","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1161\/ATVBAHA.118.312267","article-title":"Race-Based differences in lipoprotein(a)-associated risk of carotid atherosclerosis the multi-ethnic study of atherosclerosis","volume":"39","author":"Steffen","year":"2019","journal-title":"Arterioscler, Thromb, Vasc Biol"},{"key":"B9","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1016\/j.jacc.2016.11.042","article-title":"A test in context: lipoprotein(a): diagnosis, prognosis, controversies, and emerging therapies","volume":"69","author":"Tsimikas","year":"2017","journal-title":"J Am Coll Cardiol"},{"key":"B10","doi-asserted-by":"publisher","first-page":"412","DOI":"10.1001\/jama.2009.1063","article-title":"Lipoprotein(a) concentration and the risk of coronary heart disease, stroke, and nonvascular mortality","volume":"302","author":"Erqou","year":"2009","journal-title":"JAMA"},{"key":"B11","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1016\/s0021-9150(02)00026-6","article-title":"Lipoprotein (a) as a predictor of coronary heart disease: the PRIME study","volume":"163","author":"Luc","year":"2002","journal-title":"Atherosclerosis"},{"key":"B12","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1016\/j.atherosclerosis.2022.06.1023","article-title":"Sex differences of lipoprotein(a) levels and associated risk of morbidity and mortality by age: the Copenhagen general population study","volume":"355","author":"Simony","year":"2022","journal-title":"Atherosclerosis"},{"key":"B13","doi-asserted-by":"publisher","first-page":"e11","DOI":"10.15420\/japsc.2021.31","article-title":"Role of lipoprotein(a) in cardiovascular disease: a review of clinical practice","volume":"1","author":"Minami","year":"2022","journal-title":"Journal of Asian Pacific Society of Cardiology"},{"key":"B14","doi-asserted-by":"publisher","first-page":"996","DOI":"10.1161\/ATVBAHA.114.304785","article-title":"Race is a key Variable in assigning lipoprotein(a) cutoff values for coronary heart disease risk assessment","volume":"35","author":"Guan","year":"2015","journal-title":"Arterioscler, Thromb, Vasc Biol"},{"key":"B15","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1002\/clc.4960280303","article-title":"Aortic stenosis: is it simply a degenerative process or an active atherosclerotic process?","volume":"28","author":"Hughes","year":"2005","journal-title":"Clin Cardiol."},{"key":"B16","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1161\/ATVBAHA.119.313067","article-title":"Aortic valve stenosis: from basic mechanisms to novel therapeutic targets","volume":"40","author":"Goody","year":"2020","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"B17","doi-asserted-by":"publisher","first-page":"e48","DOI":"10.1161\/ATV.0000000000000147","article-title":"Lipoprotein(a): a genetically determined, causal, and prevalent risk factor for atherosclerotic cardiovascular disease: a scientific statement from the American Heart Association","volume":"42","author":"Reyes-Soffer","year":"2022","journal-title":"Arterioscler, Thromb, Vasc Biol"},{"key":"B18","doi-asserted-by":"publisher","first-page":"308","DOI":"10.1093\/eurjpc\/zwac271","article-title":"Lipoprotein(a)-related cardiovascular and all- cause mortalities in Korean adults","volume":"30","author":"Kim","year":"2023","journal-title":"Eur J Prev Cardiol"},{"key":"B19","doi-asserted-by":"publisher","first-page":"3925","DOI":"10.1093\/eurheartj\/ehac361","article-title":"Lipoprotein(a) in atherosclerotic cardiovascular disease and aortic stenosis: a European atherosclerosis society consensus statement","volume":"43","author":"Kronenberg","year":"2022","journal-title":"Eur Heart J"},{"key":"B20","doi-asserted-by":"publisher","first-page":"2150","DOI":"10.1016\/j.jacc.2019.01.070","article-title":"Lipoprotein(a) and oxidized phospholipids promote valve calcification in patients with aortic stenosis","volume":"73","author":"Zheng","year":"2019","journal-title":"J Am Coll Cardiol"}],"container-title":["Frontiers in Cardiovascular Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcvm.2024.1468566\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,21]],"date-time":"2024-10-21T04:40:28Z","timestamp":1729485628000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcvm.2024.1468566\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10,21]]},"references-count":20,"alternative-id":["10.3389\/fcvm.2024.1468566"],"URL":"https:\/\/doi.org\/10.3389\/fcvm.2024.1468566","relation":{},"ISSN":["2297-055X"],"issn-type":[{"value":"2297-055X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,10,21]]},"article-number":"1468566"}}